Diffusion Pharmaceuticals Sees Significant Progress In Its Strategic Review Process

11/14/22 6:33:44 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DFFN alert in real time by email

Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process

Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital

LifeSci-affiliated Fund Commences Proxy Contest for Control of the Diffusion Board Following Rejection of Client’s Offer

Company Believes LifeSci Proxy Campaign is Attempt to Circumvent Strategic Review Process

Date of Diffusion’s 2022 Annual Meeting of Stockholders Set for December 30, 2022

Get the next $DFFN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DFFN

Date	Price Target	Rating	Analyst

More analyst ratings

$DFFN
Press Releases

Fastest customizable press release news feed in the world

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
Approximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. ("EIP"), and a reverse stock split of outstanding Diffusion Common Stock (the "Reverse Split"). Dr. Robert Cobuzzi, President and Chief Executive Officer of Diffusion, said, "We are pleased with the outcome of to
8/15/23 4:01:02 PM ET
$DFFN
Biotechnology: Pharmaceutical Preparations
Health Care
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024 Transaction has unanimous support of both EIP Pharma and Diffusion Boards of Directors BOSTON and CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) -- EIP Pharma Inc. (EIP Pharma), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, and Diffusion Pharmaceuticals Inc. (D
3/30/23 7:00:20 AM ET
$DFFN
Biotechnology: Pharmaceutical Preparations
Health Care
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
LifeSci Special Opportunities Master Fund Announces Support for Diffusion's Ongoing, Board-led Strategic Review Process and for Diffusion's Nominees at 2022 Annual Meeting New Director to be Appointed to Diffusion Board if Strategic Transaction Not Completed by mid-2023 CHARLOTTESVILLE, Va., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd., affiliated entities and cert
12/16/22 6:30:48 AM ET
$DFFN
Biotechnology: Pharmaceutical Preparations
Health Care

$DFFN
Market Insights

Live Market Insights

Diffusion Pharmaceuticals Stockholders Approve Merger With EIP Pharma; ~71% Of Stockholders Voted In Favor Of The Transaction; Announces 1-For-1.5 Reverse Stock Split
Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5 Reverse Stock Split Merger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. ("EIP"), and a reverse stock split of outstanding Diffusion Common Stock (the "Reverse Split"). Dr. Robert Cobuzzi, President and Chief Executive Officer of Diffusion, said, "We are pleased with the outcome of
8/15/23 4:13:06 PM ET
$DFFN
Biotechnology: Pharmaceutical Preparations
Health Care
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 109 companies set new 52-week lows. 52-Week Low Highlights: The largest company in terms of market cap to set a new 52-week low was Nasdaq (NASDAQ:NDAQ). Biodexa Pharmaceuticals (NASDAQ:BDRX) was the smallest company in terms of market cap to set a new 52-week low. Sarcos Technology (NASDAQ:STRC) shares dropped the most, trading down 417.35% to reach its new 52-week low. Cineverse (NASDAQ:CNVS) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. Here is a list of stocks that set new 52-week lows on Thursday: Nasdaq (NASDAQ:NDAQ) stock achieved a new 52-week low on Thursday morning, hitting $48.90 and moving down 1.92%. Jazz P
7/6/23 12:58:38 PM ET
$VRAY
$WIA
$WIW
$XNCR
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Trusts Except Educational Religious and Charitable
Finance
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 100 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: BioNTech (NASDAQ:BNTX) was the largest, in terms of market cap, to set a new 52-week low. Vyant Bio (NASDAQ:VYNT) was the smallest, in terms of market cap, to set a new 52-week low. Soligenix (NASDAQ:SNGX)'s stock came under the most pressure, trading down 47.37% to reach a new 52-week low. Barings BDC (NYSE:BBDC) shares were the most resilient of the group, as shares actually moved up 0.0% in response to hitting its 52-week low. On Friday, the following stocks broke to new 52-week lows: BioNTech (NASDAQ:BNTX) stock achieved a new 52-week low on Friday morning, hitting $1
5/5/23 1:54:25 PM ET
$VIRX
$VLN
$VYNT
$WOLF
Biotechnology: Pharmaceutical Preparations
Health Care
Semiconductors
Technology

Diffusion Pharmaceuticals Sees Significant Progress In Its Strategic Review Process

Chat with this insight

Recent Analyst Ratings for
$DFFN

$DFFN
SEC Filings

Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$DFFN
Press Releases

Fastest customizable press release news feed in the world

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

$DFFN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Boger Joshua S

New insider Boger Joshua S claimed ownership of 561,309 shares (SEC Form 3)

SEC Form 4 filed by Alam John J

$DFFN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Diffusion Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D filed by Diffusion Pharmaceuticals Inc.

SEC Form SC 13G filed by Diffusion Pharmaceuticals Inc.

$DFFN
Leadership Updates

Live Leadership Updates

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer

Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

$DFFN
Market Insights

Live Market Insights

Diffusion Pharmaceuticals Stockholders Approve Merger With EIP Pharma; ~71% Of Stockholders Voted In Favor Of The Transaction; Announces 1-For-1.5 Reverse Stock Split

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Friday

Diffusion Pharmaceuticals Sees Significant Progress In Its Strategic Review Process

Chat with this insight

Recent Analyst Ratings for $DFFN

$DFFN SEC Filings

Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$DFFN Press Releases

Fastest customizable press release news feed in the world

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

$DFFN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Boger Joshua S

New insider Boger Joshua S claimed ownership of 561,309 shares (SEC Form 3)

SEC Form 4 filed by Alam John J

$DFFN Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Diffusion Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D filed by Diffusion Pharmaceuticals Inc.

SEC Form SC 13G filed by Diffusion Pharmaceuticals Inc.

$DFFN Leadership Updates

Live Leadership Updates

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer

Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

$DFFN Market Insights

Live Market Insights

Diffusion Pharmaceuticals Stockholders Approve Merger With EIP Pharma; ~71% Of Stockholders Voted In Favor Of The Transaction; Announces 1-For-1.5 Reverse Stock Split

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Friday

Recent Analyst Ratings for
$DFFN

$DFFN
SEC Filings

$DFFN
Press Releases

$DFFN
Insider Trading

$DFFN
Large Ownership Changes

$DFFN
Leadership Updates

$DFFN
Market Insights